SCG3

Across TCGA pan-cancer cohorts, SCG3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SCG3 data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SCG3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SCG3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where SCG3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.328	0.854	.004	27	view →
HNSC	OS	Median	All	0.540	1.000	.014	24	view →
PDAC	OS	Median	III,IV	0.937	0.592	.006	18	view →
GBM	DFS	Quartile	All	0.938	0.642	.003	5	view →
CCRCC	OS	Median	III,IV	0.286	0.858	.044	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SCG3–LUAD (OS)

Open the LUAD breakdown →